LARVOL is pleased to present a moderated discussion with top oncologists following ASCO's Annual Meeting 2021. In the video below, Dr. Kevin Knopf, Dr. Mohamed Salem, and Dr. Mark Lewis discuss the practice-changing impact of ASCO presentations in GI cancer.
On June 7, 2021, LARVOL hosted an Oncology Panel to discuss the top gastrointestinal (GI) cancer clinical trial abstracts presented during the American Society of Clinical Oncology (ASCO) Annual Meeting 2021, held on June 4-8, 2021. Dr. Kevin Knopf from the University of California, San Francisco moderated the discussion between GI cancer KOLs Dr. Mohamed Salem from Levine Cancer Institute and Dr. Mark Lewis from Intermountain Health.
The discussion covered ASCO abstract # 3500 Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC), ASCO abstract #3505 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01) and ASCO abstract #4002 First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.
Watch this video for the full discussion:
Our ASCO Panel Series covered six therapeutic areas including GI cancer. Click below to read more about them and watch their video analysis.